COSCIENS Biopharma Inc. (CSCIF) Form 6-K — May 12, 2026
COSCIENS Biopharma Inc. reported its first-quarter 2026 financial results, revealing a consolidated net income of $10.8 million, a significant turnaround from a net loss of $3.7 million in the prior-year period. This swing is primarily driven by a one-time gain of $10.9 million from the deconsolidation of its German subsidiaries, which were classified as discontinued operations following insolvency proceedings in March 2026. Revenue from continuing operations increased 36% to $1.9 million, bolstered by higher sales volumes, while gross margin improved to 42%.
Key figures
- Eps
- 3.42
- Revenue
- 1888000
- Net Income
- 10757000
- Cash Position
- 5005000
- Shares Outstanding
- 3184159
- Gross margin percentage
- 42%
- Revenue growth percentage
- 36%
- Discontinued operations gain
- 10940000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.